Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Castle Biosciences, Inc. (CSTL : NSDQ)

• Company Description    Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Number of Employees: 761

• Price / Volume Information    Yesterday's Closing Price: $20.01 Daily Weekly Monthly 20 Day Moving Average: 442,673 shares Shares Outstanding: 28.87 (millions) Market Capitalization: $577.73 (millions) Beta: 1.10 52 Week High: $35.84 52 Week Low: $15.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.57% 12.72% 12 Week -0.50% -12.81% Year To Date -24.92% -29.08%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 505 S. Friendswood Drive Suite 401 - Friendswood,TX 77546 USA ph: 866-788-9007 fax: - ir@castlebiosciences.com https://castlebiosciences.com

• General Corporate Information    Officers Derek J. Maetzold - President and Chief Executive Officer Daniel M. Bradbury - Chairperson of the Board of Directors Frank Stokes - Chief Financial Officer Kimberlee S. Caple - Director G. Bradley Cole - Director Peer Information Castle Biosciences, Inc. (CORR.) Castle Biosciences, Inc. (RSPI) Castle Biosciences, Inc. (CGXP) Castle Biosciences, Inc. (BGEN) Castle Biosciences, Inc. (GTBP) Castle Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14843C105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 28.87 Most Recent Split Date: (:1) Beta: 1.10 Market Capitalization: $577.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.11 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 39.24 PEG Ratio: - Price Ratios Price/Book: 1.31 Price/Cash Flow: 20.34 Price / Sales: 1.66 EPS Growth vs. Year Ago Period: -122.22% vs. Previous Quarter: -162.50% Sales Growth vs. Year Ago Period: 20.57% vs. Previous Quarter: 1.94% ROE 06/30/25 - - 03/31/25 - 3.41 12/31/24 - 4.24 ROA 06/30/25 - - 03/31/25 - 2.95 12/31/24 - 3.66 Current Ratio 06/30/25 - - 03/31/25 - 9.37 12/31/24 - 7.29 Quick Ratio 06/30/25 - - 03/31/25 - 9.19 12/31/24 - 7.13 Operating Margin 06/30/25 - - 03/31/25 - 4.33 12/31/24 - 5.49 Net Margin 06/30/25 - - 03/31/25 - -1.46 12/31/24 - 5.49 Pre-Tax Margin 06/30/25 - - 03/31/25 - -0.64 12/31/24 - 6.49 Book Value 06/30/25 - - 03/31/25 - 15.25 12/31/24 - 16.28 Inventory Turnover 06/30/25 - - 03/31/25 - 8.48 12/31/24 - 7.93 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.02 12/31/24 - 0.02 Debt-to-Capital 06/30/25 - - 03/31/25 - 1.99 12/31/24 - 2.09

Powered by Zacks Investment Research ©